Efficacy & Safety of KAPVAY™ Extended-Release in Children & Adolescents With Attention Deficit Hyperactivity Disorder

NCT01439126 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

135

Enrollment

INDUSTRY

Sponsor class

Conditions

Attention Deficit Hyperactivity Disorder

Interventions

DRUG: clonidine hydrochloride
DRUG: Placebo

Sponsor

Concordia Pharmaceuticals Inc., Barbados